FibroGen Inc (FGEN)
1.21
+0.06
(+5.22%)
USD |
NASDAQ |
May 31, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
FibroGen SG&A Expense (Annual): 115.25M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 115.25M |
December 31, 2022 | 124.69M |
December 31, 2021 | 123.92M |
December 31, 2020 | 106.41M |
December 31, 2019 | 135.48M |
December 31, 2018 | 63.81M |
Date | Value |
---|---|
December 31, 2017 | 51.76M |
December 31, 2016 | 46.02M |
December 31, 2015 | 44.36M |
December 31, 2014 | 36.91M |
December 31, 2013 | 24.41M |
December 31, 2012 | 18.93M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
106.41M
Minimum
2020
135.48M
Maximum
2019
121.15M
Average
123.92M
Median
2021
SG&A Expense (Annual) Benchmarks
Annovis Bio Inc | 6.244M |
Emergent BioSolutions Inc | 368.40M |
Vertex Pharmaceuticals Inc | 1.137B |
Geron Corp | 69.14M |
Nanoviricides Inc | 2.551M |